New publication 📝 BRUIN CLL-314 phase III results, published in the Journal of Clinical Oncology, show that pirtobrutinib demonstrated noninferior ORR to ibrutinib (87.0% vs 78.5%; p < 0.0035) in TN or R/R BTKi-naïve CLL/SLL. Learn more: https://loom.ly/jLklx8s #leusm #lymsm #MedNews #MedEd

New publication📝 5-year follow-up results from the phase II JULIET trial, published in the Journal of Clinical Oncology, show tisagenlecleucel had an ORR of 53.0% in patients with R/R LBCL, with the median DoR not reached. Learn more: https://loom.ly/rC-uX7Y #lymphoma #lymsm #MedNews #MedEd

New publication📝HOVON 158/NEXT STEP results, published in The Lancet Haematology, show MRD-guided ibrutinib + obinutuzumab intensification after ibrutinib + venetoclax achieved 60% CR/CRi with BM uMRD4 at 3 months in TN CLL. Learn more: https://loom.ly/iVvKXk4 #lymphoma #lymsm #MedNews #MedEd

🚨News 🚨 Health Canada approves pirtobrutinib, a non-covalent BTKi, for the treatment of patients with R/R MCL and CLL/SLL who have received ≥2 prior lines of therapy. Read more: https://loom.ly/jvX61wU #lymsm #leusm #MedEd #MedNews

New publication📝Phase III inMIND data, published in Lancet, show tafasitamab + lenalidomide + rituximab significantly improved median PFS vs placebo (22.4 vs 13.9 months; p < 0.0001) in R/R FL. Learn more: https://loom.ly/uiZeapw #lymsm #lymphoma #MedNews #MedEd

New publication 📝 Phase I data presented at #ASH25 show that surovatamig demonstrated tolerability and achieved CR rates of 86–100% across dose cohorts in heavily pretreated R/R FL patients Learn more: https://loom.ly/LAddsXI#ASH25 #lymphoma #lymsm #MedNews #MedEd

New publication📝Results from the CLL17 trial, published in @NEJM, show noninferior 3-year PFS with fixed-duration venetoclax + obinutuzumab or venetoclax + ibrutinib vs continuous ibrutinib in previously untreated CLL. Learn more: https://loom.ly/iVvKXk4 #lymphoma #lymsm #MedNews #MedEd

New publication📝 Phase II MITHIC-FL2 first results, presented at #ASH2025, show ORR and CR rates were 92% and 82%, respectively, in patients with ND, high-burden FL treated with mosunetuzumab + zanubrutinib. Learn more: https://loom.ly/B8pRi7c#ASH2025 #lymphoma #lymsm #MedNews #MedEd

New data📝Phase II preliminary results, presented by Anita Kumar at #ASH25, show the BOVen triplet combination achieved a 98% metabolic response rate in older patients with MCL, with a 2-year PFS of 86% and OS of 92%. Learn more: https://loom.ly/B8pRi7c#ASH25 #lymphoma #lymsm #MedNews #MedEd

The FDA has removed the REMS requirements for approved CAR T-cell therapies. Check out our visual abstract summarizing these changes: https://loom.ly/DAbLNQs #lymsm #Lymphoma #MedNews #MedEd

🚨 News 🚨 The FDA clears an IND application for APG-3288, a novel BTK-targeted protein degrader, for the treatment of relapsed/refractory B-cell malignancies. Read more: https://loom.ly/_qG9hog #Lymphoma #Lymsm #MedNews

New publication📝 50-month follow-up results from the phase III ECHO trial, presented at #ASH2025, show ABR improved PFS (72.5 vs 47.8 months) vs PBR in older patients with TN MCL. Learn more: https://loom.ly/B8pRi7c#ASH2025 #lymphoma #lymsm #MedNews #MedEd

Read our latest overview of class effects, treatment guidelines, and real-world evidence for BTKi in patients with CLL: https://loom.ly/Zlwwbfs #leusm #lymsm #MedEd #MedNews

In our latest podcast, Joshua Brody shared his key highlights in lymphoma and CLL from #ASH25. Listen here: https://loom.ly/a0CqZnU#ASH25 #lymsm #lymphoma #MedEd

New data📝Phase III BRUIN CLL-313 findings, presented by Wojciech Jurczak at #ASH25, show pirtobrutinib significantly improved PFS vs BR in patients with treatment-naïve CLL/SLL (HR, 0.20; 95% CI, 0.11–0.37; p < 0.0001). Learn more: https://loom.ly/B8pRi7c#ASH25 #lymphoma #lymsm #MedNews #MedEd

Joshua Brody shared his key highlights in lymphoma and CLL from #ASH25. Watch here: https://loom.ly/OSJsgR8#ASH25 #lymsm #lymphoma #MedEd

Alexey Danilov discussed results from the phase I study of bexobrutideg, a novel BTK degrader, in patients with R/R CLL, which were presented at #ASH25. Watch here: https://loom.ly/M45g2y4#ASH25 #lymsm #leusm #MedEd

Susan O’Brien, @ChaoCompCancer @UCIrvineHealth, discussed results from the CAPTIVATE trial of ibrutinib + venetoclax in patients with CLL. Watch the full video here: https://loom.ly/F7tWpYY #leusm #lymsm #MedNews #MedEd

🚨 NEWS 🚨 FDA approves a subcutaneous formulation of mosunetuzumab for the treatment of adult patients with R/R FL after ≥2 prior lines of systemic therapy, based on results from the GO29781 trial. Read more: https://loom.ly/p7QgFmU #lymphoma #lymsm #MedNews #MedEd

🚨 NEWS 🚨 Japan's Ministry of Health, Labour and Welfare approves tafasitamab in combination with rituximab + lenalidomide for adult patients with R/R FL, based on data from the phase III inMIND trial. Read more: https://loom.ly/n4AYOKI #lymphoma #lymsm #mednews

The Lymphoma Hub was pleased to speak with Alexey Danilov at #ASH25. We asked, What are the latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with R/R CLL? Watch the full video here: https://loom.ly/M45g2y4#ASH25 #lymsm #leusm #MedEd

What are the class effects, treatment guidelines, and real-world evidence for BTKi in patients with CLL? Read our latest article here: https://loom.ly/Zlwwbfs #leusm #lymsm #MedEd #MedNews

In our latest podcast, Alexey Danilov discusses results from the ongoing phase I NX-5948-301 trial of bexobrutideg in patients with R/R CLL, presented at #ASH25 Listen here: https://loom.ly/BLdORcI#ASH25 #lymsm #leusm #MedEd

Catch up on the latest developments in aggressive B-cell NHL from #ASH25, with social media coverage from the Lymphoma Hub: https://loom.ly/POS6cqk#ASH25#lymsm #leusm #MedicalCongress

Catch up on the latest developments in indolent and mantle cell NHL from #ASH25, with social media coverage from the Lymphoma Hub: https://loom.ly/FTOLNe8#ASH25#lymsm #leusm #MedicalCongress

The Lymphoma Hub was pleased to speak with Joshua Brody at #ASH25. We asked, What were your key highlights in lymphoma and CLL from the meeting? Watch here: https://loom.ly/OSJsgR8#ASH25 #lymsm #lymphoma #MedEd

What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with CLL? The Lymphoma Hub was pleased to speak to Susan O’Brien about the latest results from the CAPTIVATE trial. Listen here: https://loom.ly/EUxV_Fs #leusm #lymsm #MedNews #MedEd

Catch up on the latest developments in CLL/SLL from #ASH25, with social media coverage from the Lymphoma Hub: https://loom.ly/gh3vlu8#ASH25#lymsm #leusm #MedicalCongress

🚨 NEWS 🚨 The European Commission has approved tafasitamab + lenalidomide + rituximab for the treatment of adult patients with R/R FL after ≥1 prior line of systemic therapy, based on results from the phase III inMIND trial. Read more: https://loom.ly/w2-UR0U #Lymphoma #lymsm #MedNews #MedEd

Catch up on the latest developments in Hodgkin lymphoma and T-cell lymphoma from #ASH25, with social media coverage from the Lymphoma Hub: https://loom.ly/wivNprc#ASH25#lymsm #leusm #MedicalCongress

Learn more about the efficacy and safety of epcoritamab in patients with R/R FL from the primary results of the phase III EPCORE FL-1 trial, presented by Lorenzo Falchi at #ASH25. Watch here: https://loom.ly/s1vrQvQ#ASH25 #lymsm #lymphoma #MedEd

In our latest podcast, Lorenzo Falchi discusses the efficacy and safety findings of epcoritamab in patients with R/R FL from the primary analysis of the phase III EPCORE FL-1 trial, presented at #ASH25. Listen here: https://loom.ly/D8PdMMs#ASH25#lymsm #lymphoma #MedEd

🚨 News 🚨 The Malaysian National Pharmaceutical Regulatory Agency has approved an sNDA for selinexor for the treatment of adult patients with R/R DLBCL who have had ≥2 prior lines of therapy and are ineligible for auto-HSCT. Read more: https://loom.ly/GDZmYEI #Lymphoma #lymsm #MedNews

At #ASH25 Haifaa Abdulhaq discussed the latest updates from the phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL? Watch here: https://loom.ly/SnZzd0Y#ASH25 #lymsm #lymphoma #MedEd

The Lymphoma Hub was pleased to speak with Alexey Danilov at #ASH25. We asked, What are the latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with R/R CLL? Watch here: https://loom.ly/M45g2y4#ASH25 #lymsm #leusm #MedEd

During our latest steering committee meeting, Gareth Gregory discussed updated results from the phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL. Listen here: https://loom.ly/Mf-snvI #lymphoma #lymsm #MedEd #MedNews

🚨 NEWS 🚨 FDA grants priority review to nivolumab + AVD for adult and pediatric patients aged ≥12 years with previously untreated Stage III or IV cHL. Read more here: https://loom.ly/NgQIEgM #MedNews #lymsm #lymphoma

During our latest steering committee meeting, the panel discussed updated results from the phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL. Watch the full video here: https://loom.ly/YpxZNZM #lymphoma #lymsm #MedEd #MedNews

Learn more about the efficacy and safety of epcoritamab in an ethnically and racially diverse group of patients with R/R DLBCL from the latest analysis of the EPCORE NHL-6 trial, presented by Adelba Torres at #ASH25. Watch here: https://loom.ly/fmtCMPg#ASH25 #lymsm #lymphoma #MedEd @AuxilioMutuo

In our latest podcast, Adelba Torres discusses the efficacy and safety of epcoritamab in an ethnically/racially diverse group of patients with R/R DLBCL from the latest analysis of the phase II EPCORE NHL-6 trial, presented at #ASH25. Listen here: https://loom.ly/T2UU8x4#ASH25 #lymsm #lymphoma #MedEd

The Lymphoma Hub was pleased to speak with Lorenzo Falchi at #ASH25. We asked, What do the primary results from the phase III EPCORE FL-1 trial tell us about epcoritamab + R2 vs R2 in patients with R/R FL? Watch here: https://loom.ly/s1vrQvQ#ASH25 #lymsm #lymphoma #MedEd

Learn more about the efficacy and safety of epcoritamab in an ethnically/racially diverse group of patients with R/R DLBCL from the latest analysis of the phase II EPCORE NHL-6 trial presented by Adelba Torres at #ASH25. Watch the full video here: https://loom.ly/fmtCMPg#ASH25 #lymsm #lymphoma #MedEd

During #ASH25 the Lymphoma Hub was pleased to speak to Haifaa Abdulhaq. We asked, What do the 3-year follow-up results from the STARGLO trial tell us about Glofit-GemOx treatment in patients with R/R DLBCL? Watch here: https://loom.ly/SnZzd0Y#ASH25 #lymsm #lymphoma #MedEd

At #ASH25 the Lymphoma Hub was pleased to speak to Haifaa Abdulhaq about the latest updates from the phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL. Listen here: https://loom.ly/D5xik7w#ASH25 #lymsm #lymphoma #MedEd

The Lymphoma Hub was pleased to speak with Adelba Torres at #ASH25. We asked, What does the latest analysis of the EPCORE NHL-6 trial tell us about the use of bispecific antibodies in an ethnically/racially diverse group of patients? Watch here: https://loom.ly/fmtCMPg#ASH25#lymsm #lymphoma #MedEd

Catch up on the latest developments in lymphoma and CLL from #ASH25, with live social media coverage from the Lymphoma Hub: https://loom.ly/POS6cqk#ASH25#lymsm #leusm #MedicalCongress

🚨 NEWS 🚨 FDA approves liso-cel, a CD19-directed CAR T-cell therapy, for the treatment of patients with R/R MZL after ≥2 prior lines of systemic therapy, based on results from the TRANSCEND FL trial. Read more here: https://loom.ly/ZohfH2s #MedNews #lymsm #lymphoma

What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with CLL? The Lymphoma Hub was pleased to speak to Susan O’Brien about the latest results from the CAPTIVATE trial. Watch here: https://loom.ly/F7tWpYY #leusm #lymsm #MedNews #MedEd

🚨 News 🚨 Hong Kong Special Administrative Region approves supplemental new drug application for selinexor, an XPO1 inhibitor, for adult patients with R/R DLBCL-NOS after ≥2 lines of systemic therapy who are ineligible for HSCT. Read more: https://loom.ly/1YZkZpU #lymphoma #lymsm #MedNews

🚨 NEWS 🚨 FDA approves pirtobrutinib, a non-covalent BTKi, for the treatment of adult patients with R/R CLL/SLL previously treated with a covalent BTKi. Read more: https://loom.ly/wnwQlIQ #leusm #lymsm #MedNews #MedEd